Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine-18 flurpiridaz - GE Healthcare/Lantheus Medical Imaging

Next Previous
Drug Profile

Fluorine-18 flurpiridaz - GE Healthcare/Lantheus Medical Imaging

Alternative Names: 18F-flurpiridaz; BMS-747158; BMS-747158-02; F-18 flurpiridaz; Flurpiridaz (18F) Injection; FLYRCADO

Latest Information Update: 08 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lantheus Medical Imaging
  • Developer GE Healthcare; Lantheus Medical Imaging
  • Class Chlorinated hydrocarbons; Ethers; Fluorinated hydrocarbons; Fluorine radioisotopes; Imaging agents; Ketones; Pyridazines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease

Most Recent Events

  • 27 Mar 2025 Launched for Coronary artery disease (Diagnosis) in USA (IV)
  • 27 Mar 2025 Fluorine-18 flurpiridaz receives pass-through payment status from U.S. Centers for Medicare and Medicaid (CMS)
  • 25 Feb 2025 GE healthcare and Lantheus Medical Imaging plans to launch fluorine-18 flurpiridaz for Coronary artery disease in in the second quarter of 2025 in the USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top